Deletion of Aldose Reductase from Mice Inhibits Diabetes-Induced Retinal Capillary Degeneration and Superoxide Generation

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Tang, Jie ^a,b   Du, Yunpeng ^a   Petrash, J Mark ^c   Sheibani, Nader ^d   Kern, Timothy S ^a,e  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Heilongjiang Province Hospital   (China)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; SUPEROXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; COCULTURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENZYME INHIBITION; HISTOPATHOLOGY; LEUKOCYTE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETINA CAPILLARY; RETINA CELL; RETINA DEGENERATION; VASCULAR NECROSIS; WILD TYPE;

ALDEHYDE REDUCTASE; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; MALE; MICE; MICE, INBRED C57BL; RETINAL DEGENERATION; SUPEROXIDES;

ANIMALIA; MUS;

EID: 84876196233     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062081     Document Type: Article

References (56)

1. Kinoshita JH, (1986) Aldose reductase in the diabetic eye. Am J Ophthalmol 102: 685-692.
2. Kinoshita JH, (1990) A thirty year journey in the polyol pathway. Exp Eye Res 50: 567-573.
3. Ramana KV, Bhatnagar A, Srivastava SK, (2004) Inhibition of aldose reductase attenuates TNF-alpha-induced expression of adhesion molecules in endothelial cells. FASEB J 18: 1209-1218.
4. Ramana KV, Friedrich B, Srivastava S, Bhatnagar A, Srivastava SK, (2004) Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes 53: 2910-2920.
5. Obrosova IG, Pacher P, Szabo C, Zsengeller Z, Hirooka H, et al. (2005) Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes 54: 234-242.
6. Pladzyk A, Reddy AB, Yadav UC, Tammali R, Ramana KV, et al. (2006) Inhibition of aldose reductase prevents lipopolysaccharide-induced inflammatory response in human lens epithelial cells. Invest Ophthalmol Vis Sci 47: 5395-5403.
7. Ramana KV, Willis MS, White MD, Horton JW, DiMaio JM, et al. (2006) Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition. Circulation 114: 1838-1846.
8. Tammali R, Ramana KV, Singhal SS, Awasthi S, Srivastava SK, (2006) Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin e2 production in human colon cancer cells. Cancer Res 66: 9705-9713.
9. Cheung AK, Lo AC, So KF, Chung SS, Chung SK, (2007) Gene deletion and pharmacological inhibition of aldose reductase protect against retinal ischemic injury. Exp Eye Res 85: 608-616.
10. Lo AC, Cheung AK, Hung VK, Yeung CM, He QY, et al. (2007) Deletion of aldose reductase leads to protection against cerebral ischemic injury. J Cereb Blood Flow Metab 27: 1496-1509.
11. Yadav UC, Srivastava SK, Ramana KV, (2007) Aldose reductase inhibition prevents endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 48: 4634-4642.
12. Reddy AB, Srivastava SK, Ramana KV, (2009) Anti-inflammatory effect of aldose reductase inhibition in murine polymicrobial sepsis. Cytokine 48: 170-176.
13. Ramana KV, Srivastava SK, (2010) Aldose reductase: a novel therapeutic target for inflammatory pathologies. Int J Biochem Cell Biol 42: 17-20.
14. Yadav UC, Srivastava SK, Ramana KV, (2010) Understanding the role of aldose reductase in ocular inflammation. Curr Mol Med 10: 540-549.
15. Srivastava SK, Yadav UC, Reddy AB, Saxena A, Tammali R, et al. (2011) Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chem Biol Interact 191: 330-338.
16. Yadav UC, Ramana KV, Srivastava SK, (2011) Aldose reductase inhibition suppresses airway inflammation. Chem Biol Interact 191: 339-345.
17. Chung SS, Chung SK, (2005) Aldose reductase in diabetic microvascular complications. Curr Drug Targets 6: 475-486.
18. Robison WG Jr, Kador PF, Akagi Y, Kinoshita JH, Gonzalez R, et al. (1986) Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat. Diabetes 35: 295-299.
19. Kador PF, Akagi Y, Terubayashi H, Wyman M, Kinoshita JH, (1988) Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 106: 1099-1102.
20. Robison WG Jr, Nagata M, Laver N, Hohman TC, Kinoshita JH, (1989) Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Invest Ophthalmol Vis Sci 30: 2285-2292.
21. Akagi Y, Kador PF, (1990) Effect of aldose reductase inhibitors on the progression of retinopathy in galactose-fed dogs. Exp Eye Res 50: 635-639.
22. Robison WG Jr, Tillis TN, Laver N, Kinoshita JH, (1990) Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor. Exp Eye Res 50: 355-366.
23. Kador PF, Takahashi Y, Sato S, Wyman M (1991) Aldose reductase, retinal vessel changes and cataracts in galactose-fed dogs. In: Rifkin H, Colwell JA, Taylor SI, editors. Diabetes 1991. Amsterdam: Elsevier Science Publishers. pp. 373-378.
24. Sorbinil Retinopathy Trial Research Group (1990) A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 108: 1234-1244.
25. Engerman RL, Kern TS, (1993) Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs. Diabetes 42: 820-825.
26. Engerman RL, Kern TS, Garment MB, (1993) Capillary basement membrane in retina, kidney, and muscle of diabetic dogs and galactosemic dogs and its response to 5 years aldose reductase inhibition. J Diab Compl 7: 241-245.
27. Kern TS, Engerman RL, (1995) Galactose-induced retinal microangiopathy in rats. Invest Ophthalmol Vis Sci 36: 490-496.
28. Ho HT, Chung SK, Law JW, Ko BC, Tam SC, et al. (2000) Aldose reductase-deficient mice develop nephrogenic diabetes insipidus. Mol Cell Biol 20: 5840-5846.
29. Laver NM, Robison WG Jr, Pfeffer BA, (1993) Novel procedures for isolating intact retinal vascular beds from diabetic humans and animal models. Invest Ophthalmol Vis Sci 34: 2097-2104.
30. Du Y, Miller CM, Kern TS, (2003) Hyperglycemia increases mitochondrial superoxide in retina and retinal cells. Free Radic Biol Med 35: 1491-1499.
31. Li G, Tang J, Du Y, Lee CA, Kern TS, (2011) Beneficial effects of RAGE-Ig fusion protein on early diabetic retinopathy and tactile allodynia. Molecular Vision 17: 3156-3165.
32. Cohn VH, Lyle J, (1966) A fluorometric assay for glutathione. Anal Biochem 14: 434-440.
33. Su X, Sorenson CM, Sheibani N, (2003) Isolation and characterization of murine retinal endothelial cells. Mol Vis 9: 171-178.
34. Li G, Veenstra AA, Talahalli RR, Wang X, Gubitosi-Klug RA, et al. (2012) Marrow-Derived Cells Regulate the Development of Early Diabetic Retinopathy and Tactile Allodynia in Mice. Diabetes.
35. Talahalli R, Zarini S, Tang J, Li G, Murphy R, et al. (2012) Leukocytes regulate retinal capillary degeneration in the diabetic mouse via generation of leukotrienes. J Leukoc Biol.
36. Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, et al. (2003) Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 52: 864-871.
37. Drel VR, Pacher P, Ali TK, Shin J, Julius U, et al. (2008) Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. Int J Mol Med 21: 667-676.
38. Gerhardinger C, Dagher Z, Sebastiani P, Park YS, Lorenzi M, (2009) The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes 58: 1659-1667.
39. Hattori T, Matsubara A, Taniguchi K, Ogura Y, (2010) Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo. Curr Eye Res 35: 146-154.
40. Ramana KV, Srivastava SK, (2006) Mediation of aldose reductase in lipopolysaccharide-induced inflammatory signals in mouse peritoneal macrophages. Cytokine 36: 115-122.
41. Shoeb M, Yadav UC, Srivastava SK, Ramana KV, (2011) Inhibition of aldose reductase prevents endotoxin-induced inflammation by regulating the arachidonic acid pathway in murine macrophages. Free Radic Biol Med 51: 1686-1696.
42. Pandey S, Srivastava SK, Ramana KV, (2012) A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases. Expert Opin Investig Drugs 21: 329-339.
43. Abdillahi M, Ananthakrishnan R, Vedantham S, Shang L, Zhu Z, et al. (2012) Aldose reductase modulates cardiac glycogen synthase kinase-3beta phosphorylation during ischemia-reperfusion. Am J Physiol Heart Circ Physiol 303: H297-308.
44. Spite M, Baba SP, Ahmed Y, Barski OA, Nijhawan K, et al. (2007) Substrate specificity and catalytic efficiency of aldo-keto reductases with phospholipid aldehydes. Biochem J 405: 95-105.
45. Ruiz FX, Gallego O, Ardevol A, Moro A, Dominguez M, et al. (2009) Aldo-keto reductases from the AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels. Chem Biol Interact 178: 171-177.
46. Cheung AK, Fung MK, Lo AC, Lam TT, So KF, et al. (2005) Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes 54: 3119-3125.
47. MacGregor LC, Matschinsky FM, (1985) Treatment with aldose reductase inhibitor or with myo-inositol arrests deterioration of the electroretinogram of diabetic rats. J Clin Invest 76: 887-889.
48. Hotta N, Koh N, Sakakibara F, Nakamura J, Hamada Y, et al. (1995) An aldose reductase inhibitor, TAT, prevents electroretinographic abnormalities and ADP-induced hyperaggregability in streptozotocin-induced diabetic rats. Eur J Clin Invest 25: 948-954.
49. Hotta N, Koh N, Sakakibara F, Nakamura J, Hara T, et al. (1997) Effect of an aldose reductase inhibitor on abnormalities of electroretinogram and vascular factors in diabetic rats. Eur J Pharmacol 326: 45-51.
50. Samuels IS, Lee CA, Petrash JM, Peachey NS, Kern TS (2012) Exclusion of Aldose Reductase as a mediator of ERG deficits in a mouse model of diabetic eye disease. Visual Neuroscience In press.
51. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, et al. (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. Faseb J 18: 1450-1452.
52. Zheng L, Du Y, Miller C, Gubitosi-Klug RA, Ball S, et al. (2007) Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia 50: 1987-1996.
53. Du Y, Smith MA, Miller CM, Kern TS, (2002) Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem 80: 771-779.
54. El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB, (2003) High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 44: 3135-3143.
55. Papezikova I, Pekarova M, Chatzopoulou M, Nicolaou I, Demopoulos V, et al. (2008) The effect of aldose reductase inhibition by JMC-2004 on hyperglycemia-induced endothelial dysfunction. Neuro Endocrinol Lett 29: 775-778.
56. Du Y, Tang J, Li G, Berti-Mattera L, Lee CA, et al. (2010) Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function. Invest Ophthalmol Vis Sci 51: 2158-2164.